Acute Kidney Injury in Upper GI Bleeding Patients (NCT07636083) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Acute Kidney Injury in Upper GI Bleeding Patients
Egypt200 participantsStarted 2026-05-15
Plain-language summary
This study aims to evaluate the incidence of acute kidney injury (AKI) among patients presenting with acute upper gastrointestinal bleeding (UGIB) at Sohag University Hospitals, and to identify predictors associated with renal impairment in these patients.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients aged 18 years or older
* Patients presenting with clinical features suggestive of acute upper gastrointestinal bleeding (UGIB), including hematemesis, coffee-ground vomiting, or melena
* Diagnosis of UGIB confirmed by upper gastrointestinal endoscopy or strong clinical evidence when endoscopy is not immediately available
* Patients admitted to Sohag University Hospitals (medical wards or intensive care unit)
* Availability of renal function data, including at least one serum creatinine measurement at admission and serial measurements during hospitalization
* Availability of baseline renal function (previous serum creatinine within 3-12 months) or estimable baseline during hospitalization
Exclusion Criteria:
* Patients with end-stage renal disease (ESRD) on chronic dialysis
* Patients with a history of renal transplantation
* Patients with advanced chronic kidney disease stage 5 (eGFR \<15 mL/min/1.73 m²) not on dialysis
* Patients with lower gastrointestinal bleeding
* Patients with incomplete or missing essential renal function data
* Patients discharged or deceased within 24 hours of hospital admission
* Pregnant patients
* Patients with acute kidney injury at presentation due to causes other than UGIB
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is focused on studying how often acute kidney injury occurs in patients with upper GI bleeding — does my current situation put me at higher risk for developing AKI alongside my bleeding, and is that something my care team is already monitoring for?
2Since this trial is not yet recruiting, it's not an option for me right now — but are there other active studies or registries looking at kidney complications in upper GI bleeding patients that I could potentially participate in?
3The trial is measuring AKI using something called KDIGO criteria — can you explain what those criteria are and whether my kidney function is being tracked against those benchmarks as part of my current care?
4Because this appears to be an observational study measuring how common AKI is rather than testing a new treatment, what does my doctor think the current standard of care is for protecting my kidneys if I have or develop upper GI bleeding?
5Given that this trial is still in the pre-recruitment phase and focused on understanding the problem rather than offering a new therapy, what signs of kidney stress should I or my family watch for, and at what point would my doctor want to intervene?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of Acute Kidney Injury (AKI) According to KDIGO Criteria
Timeframe: From hospital admission through hospital discharge, up to 30 days